Inspection Findings:
2. Resident 35 was admitted to the facility in 5/2022 with diagnoses including bipolar disorder and a hip fracture.
A 3/14/25 physician order stated Resident 35 was to receive two 8.6 mg tablets of senna twice a day for constipation and the medication was to be held for loose stools. The medication was scheduled to be received between 6:00 AM and 10:00 AM for the AM dose and between 4:00 PM and 7:00 PM for the PM dose.
Review of Resident 35's 4/2025 and 5/2025 MARs revealed Resident 35 received her/his senna medication twice a day every day from 4/1/25 through 5/7/25.
Review of Resident 35's 4/8/25 through 5/7/25 Bowel Movement Consistency records revealed the following errors of administration of senna:
- On 4/8/25 at 3:17 AM Resident 35 had a type 7 bowel movement (Watery, no solid pieces. Entirely liquid). On 4/8/25 Resident 35 received her/his AM and PM doses of senna. On 4/8/25 at 7:09 PM Resident 35 had bowel movement recorded at type 7.
- On 4/10/25 at 7:30 PM Resident 35 had a type 6 bowel movement (Fluffy pieces with ragged edges, a mushy stool). Resident 35 received her/his AM dose of senna on 4/11/25. Resident 35 did not experience a normal consistency bowel movement until 4/11/25 at 1:59 PM.
- On 4/13/25 at 9:19 PM Resident 35 had a type 6 bowel movement. On 4/14/25 at 5:59 AM Resident 35 had another type 6 bowel movement. Resident 35 received her/his AM dose of senna on 4/14/25. Resident 35 did not experience a normal consistency bowel movement until 4/14/25 at 1:31 PM.
- On 4/17/25 at 12:59 PM Resident 35 had a type 7 bowel movement. On 4/17/25 at 5:04 PM Resident 35 had another type 7 bowel movement. Resident 35 received her/his PM dose of senna on 4/17/25 and her/his AM dose on 4/18/25. Resident 35 did not experience a normal consistency bowel movement until 4/18/25 at 12:59 PM.
- On 4/21/25 at 4:36 PM and 6:06 PM Resident 35 had type 6 bowel movements. Resident 35 received her/his 4/21/25 PM and 4/22/25 AM doses of senna, but did experience a normal consistency bowel movement until 4/12/25 at 12:37 PM.
- On 4/26/25 at 3:33 PM Resident 35 had a type 7 bowel movement. Resident 35 received her/his PM dose senna on 4/26/25, her/his AM and PM doses of senna on 4/27/25, and her/his AM dose of senna on 4/28/25. Resident 35 did not experience a normal consistency bowel movement until 4/28/25 at 1:35 PM.
- On 5/5/25 at 8:36 PM Resident 35 had a type 6 bowel movement. Resident 35 received her/his AM dose of senna on 5/6/25. Resident 35 did not experience a normal consistency bowel movement until 5/6/25 at 1:10 PM.
On 5/8/25 at 9:42 AM Staff 27 (CNA) stated she had been instructed to report a loose stool bowel movement, which was at type 6 or type 7, to the CMA and charge nurse.
On 5/8/25 at 9:53 AM Staff 4 (RNCM) stated she considered type 6 and type 7 to be loose stool. Staff 4 stated none of the bowel movement consistency ratings included the words "loose stool" which made it challenging to define. Staff 4 confirmed Resident 35's senna medication should have been withheld until her/his stool consistency returned to normal after experiencing loose stool on the dates listed above.
, Based on interview and record review it was determined that the facility failed to ensure residents were free from unnecessary bowel and antihypotensive medications for 2 of 5 sampled resident (#s 20 and 35) reviewed for unnecessary medications. This placed the resident at risk for adverse side effects from medication complications. Findings include:
1. Resident 20 was admitted to the facility in 3/2025 with the diagnosis including hypotension.
Resident 20's 3/21/25 through 4/22/25 Physician Orders indicated the resident received midodrine (used to raise blood pressure) three times daily and was to be held for SBP (systolic blood pressure) greater than 120.
A review of Resident 20's 3/2025 and 4/2025 MARs revealed Resident 20 received the midodrine on the following dates with the SBP above 120:
-3/23/2025 AM dose, SBP was 122.
-3/23/2025 AM dose, SBP was 122.
-3/24/2025 Mid-day dose, SBP was 121.
-3/27/2025 AM dose, SBP was 131.
-3/27/2025 Mid-day dose, SBP was 131.
-3/27/2025 PM dose, SBP was 130.
-3/29/2025 PM dose, SBP was 127.
-3/31/2025 PM dose, SBP was 132.
-4/11/2025 AM dose, SBP was 146.
-4/11/2025 Mid-day dose, SBP was 146.
-4/12/2025 PM dose, SBP was 136.
-4/14/2025 AM dose, SBP was 145.
-4/14/2025 Mid-day dose, SBP was 145.
-4/17/2025 AM dose, SBP was 134.
-4/17/2025 Mid-day dose, SBP was 134.
-4/18/2025 AM dose, SBP was 141.
-4/18/2025 Mid-day dose, SBP was 141.
-4/19/2025 PM dose, SBP was 140.
-4/21/2025 PM dose, SBP 137.
Resident 20's 4/23/25 through 5/9/25 Physician Orders indicated the resident received midodrine three times daily and was to be held for SBP greater than 130.
A review of Resident 20's 4/2025 and 5/2025 MARs revealed Resident 20 received the midodrine on the following dates with the SBP above 130:
-4/25/2025 AM dose, SBP 140.
-4/25/2025 PM dose, SBP was 140.
-5/1/2025 AM dose, SBP was 132.
-5/1/2025 Mid-day dose, SBP was 142.
-5/2/2025 AM dose, SBP was 138.
On 5/8/25 at 9:11 AM Staff 15 (LPN) stated she administered the midodrine medication to Resident 20 on 5/2/25 when she should not have, as her/his SBP above 130.
On 5/8/25 at 1:12 PM Staff 24 (LPN) stated Resident 20's midodrine should have been held when her/his SBP above 130.
On 5/8/25 at 1:19 PM Staff 2 (DNS) reviewed Resident 20s's MARs from 3/2025, 4/2025, and 5/2025 and acknowledged the medication was given unnecessarily 24 times when it should have been held.
Plan of Correction:
PCP will be notified of medication errors as identified during annual survey for Midodrine by the RCM or designee.
PCP will review orders for Midodrine for Resident 20 to ensure that they would like to continue with the current hold parameters.
PCP will be notified of medication errors for Senna that were identified during annual survey by the RCM or designee.
PCP will review Resident 35 bowel regimen medications to ensure that current medications are best to be continued as ordered, as well as ensure that the hold orders in place are appropriate to manage medical diagnosis.
All residents are at risk for being impacted by this deficient practice.
Director of Nursing or designee will hold an all-nursing in-service to review the importance of accurately reading and ensuring they are following medication administration with hold orders or parameters.
Director of Nursing or designee will review orders to determine which residents have hold orders and or parameters and keep an active list when new orders are written for auditing purposes.
RCM or designee will audit weekly to ensure that hold orders and parameters are being followed as ordered and intervene accordingly.
RCM or designee will bring the results of these audit to QAPI for 3 cycles or until deficient practice has resolved.